This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Zidebactam
- DrugBank Accession Number
- DB13090
- Background
Zidebactam is under investigation in clinical trial NCT02674347 (MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Zidebactam (DB13090)
- Weight
- Average: 391.4
Monoisotopic: 391.11616921 - Chemical Formula
- C13H21N5O7S
- Synonyms
- Zidebactam
- External IDs
- WCK 5107
- WCK-5107
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Beta amino acids and derivatives / Piperidinecarboxamides / 1,3-diazepanes / Imidazolidinones / Diacylhydrazines / Organic sulfuric acids and derivatives / Dialkylamines / Azacyclic compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- 1,3-diazepane / 2-piperidinecarboxamide / 3-piperidinecarboxamide / Aliphatic heteropolycyclic compound / Alpha-amino acid amide / Amine / Azacycle / Beta amino acid or derivatives / Carbonyl group / Carboxylic acid hydrazide show 16 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- YPM97423DB
- CAS number
- 1436861-97-0
- InChI Key
- YCZPXRQPDCXTIO-BBBLOLIVSA-N
- InChI
- InChI=1S/C13H21N5O7S/c19-11(8-2-1-5-14-6-8)15-16-12(20)10-4-3-9-7-17(10)13(21)18(9)25-26(22,23)24/h8-10,14H,1-7H2,(H,15,19)(H,16,20)(H,22,23,24)/t8-,9-,10+/m1/s1
- IUPAC Name
- [(1R,2S,5R)-7-oxo-2-({[(3R)-piperidin-3-yl]formohydrazido}carbonyl)-1,6-diazabicyclo[3.2.1]octan-6-yl]oxidanesulfonic acid
- SMILES
- OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NNC(=O)[C@@H]2CCCNC2)C1=O
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Acute Pyelonephritis(APN) / Complicated Urinary Tract Infection 1 1 Completed Not Available Healthy Subjects (HS) 1 1 Completed Not Available Serious Gram-negative Infections 1 1 Completed Basic Science Healthy Subjects (HS) 1 1 Completed Other Impaired Renal Function 1 1 Recruiting Treatment Bacterial Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.13 mg/mL ALOGPS logP -2 ALOGPS logP -3.3 Chemaxon logS -2.3 ALOGPS pKa (Strongest Acidic) -2 Chemaxon pKa (Strongest Basic) 9.16 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 157.38 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 85.63 m3·mol-1 Chemaxon Polarizability 36.22 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 21, 2016 02:55 / Updated at February 21, 2021 18:54